We AreKrystal Biotech’s Vyjuvek: A Topical Triumph Driving Gains Krystal Biotech's (NASDAQ:KRYS) stock has risen another 25.6% since my previous "strong buy" recommendation in February.  Seeking AlphaBack then, I wrote about their Q4 earnings report, which showed strong sales and high patient compliance for Vyjuvek, Krystal Biotech's dystrophic epidermolysis bullosa (DEB) topical therapy. Furthermore, the company was already reporting net income, which surprised me given that Vyjuvek had only recently e ...